We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+104.8%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$189M
AUM Growth
–
Cap. Flow
+$150M
Cap. Flow %
79.7%
Top 10 Hldgs %
55.62%
Holding
62
New
61
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
+$19.9M
2
KURA icon
Kura Oncology
KURA
+$9.14M
3
BBIO icon
BridgeBio Pharma
BBIO
+$7.48M
4
VINC
Vincerx Pharma, Inc. Common Stock
VINC
+$6.35M
5
XLRN
Acceleron Pharma
XLRN
+$5.28M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 80.89%
2 Financials 1.08%
3 Consumer Staples 0.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GBT
26
DELISTED
Global Blood Therapeutics, Inc.
GBT
$2.17M 1.15%
+50,000
New +$2.47M
AXSM icon
27
CALL
Axsome Therapeutics
AXSM
$11.7B
$2.04M 1.08%
+25,000
New +$1.87M
CYPH
28
Cypherpunk Technologies Inc
CYPH
$78.3M
$2.04M 1.08%
+90,460
New +$1.72M
SLDB icon
29
CALL
Solid Biosciences
SLDB
$850M
$1.9M 1%
+16,667
New +$1.05M
ASND icon
30
Ascendis Pharma A/S
ASND
$16.6B
$1.67M 0.88%
+10,000
New +$1.65M
MGTX icon
31
MeiraGTx Holdings
MGTX
$1.13B
$1.51M 0.8%
+100,000
New +$1.41M
BFLY icon
32
Butterfly Network
BFLY
$1.73B
$1.48M 0.79%
+75,000
New +$960K
CYTK icon
33
Cytokinetics
CYTK
$10.9B
$1.46M 0.77%
+70,000
New +$1.28M
LUNG icon
34
Pulmonx
LUNG
$57.4M
$1.38M 0.73%
+20,000
New +$979K
MRSN
35
DELISTED
Mersana Therapeutics
MRSN
$1.33M 0.71%
+2,000
New +$1.11M
CLDX icon
36
Celldex Therapeutics
CLDX
$2.8B
$1.31M 0.7%
+75,000
New +$1.35M
PAND
37
DELISTED
Pandion Therapeutics Inc. Common Stock
PAND
$1.19M 0.63%
+80,000
New +$1.11M
TNGX icon
38
Tango Therapeutics
TNGX
$4.54B
$1.14M 0.61%
+100,000
New +$1.05M
SKIN icon
39
SkinHealth Systems
SKIN
$106M
$1.13M 0.6%
+100,000
New +$1.08M
BGMS
40
Bio Green Med Solution Inc
BGMS
$5.04M
$918K 0.49%
+33
New +$505K
BYSI icon
41
BeyondSpring
BYSI
$51.8M
$915K 0.49%
+75,000
New +$986K
IOVA icon
42
Iovance Biotherapeutics
IOVA
$2.24B
$909K 0.48%
+19,600
New +$778K
DRNA
43
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$881K 0.47%
+40,000
New +$881K
NARI
44
DELISTED
Inari Medical, Inc. Common Stock
NARI
$873K 0.46%
+10,000
New +$706K
KALV
45
DELISTED
KalVista Pharmaceuticals
KALV
$855K 0.45%
+45,000
New +$772K
AXSM icon
46
Axsome Therapeutics
AXSM
$11.7B
$815K 0.43%
+10,000
New +$748K
PCVX icon
47
Vaxcyte
PCVX
$8.02B
$797K 0.42%
+30,000
New +$1.12M
RCOR
48
DELISTED
Renovacor, Inc.
RCOR
$794K 0.42%
+75,000
New +$744K
IMTXW
49
DELISTED
Immatics N.V. Warrants
IMTXW
$699K 0.37%
+242,855
New +$696K
SIOX
50
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$695K 0.37%
+250,000
New +$728K
1
2
3

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q4 2020 Portfolio in Review

Q4 2020 is the first quarter with a 13F filing on record for Affinity Asset Advisors, which disclosed 62 positions worth $189M. Its ten largest holdings account for 56% of the portfolio.

Its largest position is Eidos Therapeutics, Inc. Common Stock: 225,000 shares worth $29.6M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, followed by Financials and Consumer Staples.

  • Affinity Asset Advisors's largest Q4 2020 buy was Eidos Therapeutics, Inc. Common Stock: 225,000 shares worth $29.6M.
  • Affinity Asset Advisors's ten largest holdings make up 56% of its $189M portfolio in Q4 2020.
  • Affinity Asset Advisors disclosed 62 positions in Q4 2020, its first 13F filing on record.

Based on Affinity Asset Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.